# A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

> **NCT02215447** · PHASE2 · UNKNOWN · sponsor: **Barwon Health** · enrollment: 4 (actual)

## Conditions studied

- Gastrointestinal Neuroendocrine Carcinomas

## Interventions

- **DRUG:** NAB paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02215447
- **Lead sponsor:** Barwon Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2018-11
- **Final completion:** 2020-10
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2017-11-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215447, "A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02215447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*